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Alzheimer’s disease (AD) is the most common cause of dementia in the elderly, aﬀecting several million of people worldwide.
PathologicalchangesintheADbrainincludethepresenceofamyloidplaques,neuroﬁbrillarytangles,lossofneuronsandsynapses,
and oxidative damage. These changes strongly associate with mitochondrial dysfunction and stress of the endoplasmic reticulum
(ER).Mitochondrialdysfunctionisintimatelylinkedtotheproductionofreactiveoxygenspecies(ROS)andmitochondrial-driven
apoptosis, which appear to be aggravated in the brain of AD patients. Concomitantly, mitochondria are closely associated with ER,
and the deleterious crosstalk between both organelles has been shown to be involved in neuronal degeneration in AD. Stimuli
that enhance expression of normal and/or folding-defective proteins activate an adaptive unfolded protein response (UPR) that,
if unresolved, can cause apoptotic cell death. ER stress also induces the generation of ROS that, together with mitochondrial ROS
and decreased activity of several antioxidant defenses, promotes chronic oxidative stress. In this paper we discuss the critical role
of mitochondrial and ER dysfunction in oxidative injury in AD cellular and animal models, as well as in biological ﬂuids from AD
patients. Progress in developing peripheral and cerebrospinal ﬂuid biomarkers related to oxidative stress will also be summarized.
1. GeneralIntroduction
Alzheimer’s disease (AD) is the most common form of
dementia with a progressive course. AD pathology evidences
neuronal damage in speciﬁc vulnerable brain regions and
circuits involved in memory and language, namely, the hip-
pocampus and cerebral cortex, which appears to be preceded
bysynapticandneuronaldysfunction.Fromapathologyper-
spective, the presence of extracellular plaques, mainly com-
posed of amyloid beta peptide (Aβ), a 39- to 42-aminoacid
residue peptide, derived from the processing of amyloid
precursor protein (APP), and intraneuronal neuroﬁbrillary
tangles, consisting of tau protein aggregates, constitute,
important hallmarks of the disease and serve, as a dividing
line between AD and other dementias [1–4]. Demented
individuals who do not have plaques and tangles does not
qualify for a diagnosis of AD, but the simple presence
of plaques and tangles do not distinguish demented from
nondemented individuals since brains of aged nondemented
individuals frequently contain plaques and tangles [3].
Although the etiology of AD is largely unknown, it has
been hypothesized that multiple factors, including genetic
components, oxidative stress, intracellular and/or extra-
cellular accumulation of Aβ, excitotoxicity, inﬂammation,
mitochondrial dysfunction, alteration of cytoskeleton and
synapse components and neuronal loss, may play important
roles in the onset of the disease [5]. One hypothesis that may
account for the heterogeneous nature of AD and the fact that
aging is the most obvious risk factor is the increased gener-
ation of reactive oxygen species (ROS); indeed, neurons are
extremely sensitive to attack by destructive free radicals [6].
2. Evidence of OxidativeStress in AD Brain
The“oxidativestresstheory”ofagingholdsthataprogressive
and irreversible accumulation of oxidative damage caused by2 International Journal of Cell Biology
ROS impacts on critical aspects of the senescence process,
contributing to impaired physiological function, increasing
incidence of disease, along with a reduction in life span
[7]. Although low and intermediary levels of ROS are
physiologically important, high ROS concentrations above
the clearance capacity of the cell cause oxidative stress, mito-
chondrial dysfunction, cellular damage, and, in numerous
cases, cell death [8], thus pointing oxidative stress as a
potential unifying mechanism contributing to age-related
pathologies [7] and, in particular, to AD [9, 10].
Lipid peroxidation is one of the major outcomes of
free-radical-mediated injury leading to the generation of
a variety of relatively stable end products. The ones that
have been most extensively studied, both in brain and
biological ﬂuids, such as cerebrospinal ﬂuid (CSF), plasma,
urine of AD and mild cognitive impairment (MCI) patients,
are malondialdehyde (MDA), trans-4-hydroxy-2-nonenal
(HNE), and F2-isoprostanes (F2-IsoPs). Indeed, several
studies have demonstrated signiﬁcantly increased levels of
MDA and thiobarbituric acid reactive substances (TBARS)
in AD [11–13] and MCI brains [14], particularly in regions
where neuroﬁbrillary tangles and senile plaques typically
accumulate. HNE, one of the most toxic products of lipid
peroxidation,is,likeMDA,diﬀusibleandhighlyreactivewith
other biomolecules being able to covalently modify proteins,
thus aﬀecting their function. Increased levels of free HNE
and HNE-protein adducts have been described in the brains
of MCI and AD patients compared to controls [15–19]. In
addition, increased levels of F2-IsoPs have been documented
in diﬀerent brain regions of AD in comparison to cognitively
normal individuals [20–22]. This increase of F2-IsoPs was
demonstrated to be speciﬁc of AD-type dementia and did
not occur in cases of frontotemporal dementia [21]. F2-
IsoPs have also been investigated in brain of MCI subjects.
Increased levels of these lipid peroxidation products were
documented in diﬀerent brain regions of MCI subjects
compared to controls [23]; however these data were not
conﬁrmed by other authors [24].
Within proteins, all amino acids can be attacked by ROS,
but sulphur-containing and aromatic amino acids are the
most susceptible. The oxidation of amino acids mainly leads
to the formation of carbonyl groups, while peroxynitrite can
nitrate tyrosine groups and form the stable compound 3-
nitrotyrosine (3-NT). Increased levels of protein carbonyls
have been detected in the superior and middle temporal
gyri of patients with early-stage AD and MCI and also
in the hippocampus and parietal lobe of AD patients
compared to controls [14, 25, 26], but unchanged in the
cerebellum, which is consistent with the regional pattern of
histological changes in AD. On the other hand, increased
3-NT immunoreactivity has been also detected in regions
of the cerebral cortex aﬀected by neurodegeneration in
AD patients [27], with a distribution similar to protein
carbonyls. Moreover, high levels of protein nitration were
found in inferior parietal lobes and hippocampi of MCI
patients [28]. Protein oxidation in AD does not seem to
be a random process but rather involves speciﬁcally more
susceptible proteins that have been identiﬁed through redox
proteomic studies [29]. Many of the proteins that have been
identiﬁed so far, as oxidatively modiﬁed in the brain of AD
patients and MCI subjects, are either mitochondrial proteins
or proteins that are known to interact with mitochondria;
these include glyceraldehyde 3-phosphate dehydrogenase
(GAPDH), voltage-dependent anion channel (VDAC), lac-
tate dehydrogenase (LDH), malate dehydrogenase (MDH),
adenosine triphosphate (ATP) synthase-alpha chain, beta-
actin and/or aconitase [18, 30–32].
ROS,andparticularlythehydroxylradical,canreactwith
allcomponentsoftheDNAmolecule,causingdiﬀerentkinds
of damage. DNA injury has been investigated in AD and
MCI subjects mainly through the analysis of DNA strand
breaks and the presence of speciﬁc oxidized DNA bases and
adducts, of which 8-hydroxy-2 -deoxyguanosine (8-OHdG)
is the most commonly investigated. Several postmortem
studies have reported signiﬁcant DNA fragmentation in the
brain of AD subjects compared to nondemented controls,
especially in areas that are more prone to neurodegeneration
[33–36]. A buildup of 8-OHdG was detected in brain
tissue from AD subjects, that was most prominent in
mitochondrial DNA (mtDNA) of the parietal cortex [37].
These results were conﬁrmed by another report showing that
the presence of oxidized nucleosides was inversely related
to the neuroﬁbrillary tangle content [38], further suggesting
that DNA oxidation could precede lesion formation. This
hypothesis was further corroborated by a study by Wang and
coauthors [39] who observed higher indices of oxidation in
mtDNA from neocortical regions of MCI subjects compared
to controls, but similar to the ones observed in AD patients,
suggesting that DNA oxidation was indeed an early event
in the pathogenesis of the disease. RNA is more vulnerable
to oxidation than DNA and can be easily attacked by
the hydroxyl radical. Several studies evaluated the levels
of 8-hydroxyguanosine (8-OHG) as a marker of oxidative
damage to RNA. Immunohistochemical analysis of neurons
in particularly vulnerable brain areas of AD patients showed
a marked accumulation of 8-OHG, that was negatively
correlated with the duration of the disease and the extent
of Aβ deposition [40]. These ﬁndings have been further
extended by Shan and collaborators that showed a large
increase in the extent of messenger RNA (mRNA) oxidation
inthefrontalcortex,butnotinthecerebellumofADpatients
[41, 42]. It was also demonstrated that increased levels of 8-
OHG in the parahippocampal gyrus were already present in
MCI subjects, compared to controls, but similar to the levels
found in AD patients [43], suggesting that RNA oxidative
damage is an early event in AD pathology.
Very recently, multiple biochemical markers of oxida-
tive stress and antioxidant defenses were analyzed in
frontal cortex postmitochondrial supernatant, mitochon-
drial, and synaptic fractions from age-matched noncogni-
tively impaired, mild cognitive impairment (MCI), mild AD,
a n dA Ds u b j e c t s[ 44]. In this study, a strong correlation was
observed between levels of synaptic lipid peroxidation, pro-
tein oxidation and nitration, and the subjects’ global cogni-
tive status. Changes in levels of the antioxidants glutathione
(GSH), superoxide dismutase (SOD), and catalase (CAT)
also strongly correlated with the minimental status exam-
ination (MMSE) score [45]. Previous studies found bothInternational Journal of Cell Biology 3
increased [11] and reduced activity of antioxidant enzymes
in AD [12] and MCI brain [46].
In studies assessing oxidative damage in brain, the
possibility of artifacts due to postmortem delay cannot be
completely ruled out. However, in most of the referred stud-
ies postmortem interval was conveniently short (1–5 hours),
matched between patients and control samples and therefore
should not have a signiﬁcant eﬀect on the discussed param-
eters. In fact, a few studies [33, 47] have examined the inﬂu-
enceofpostmortemdelayinoxidativedamagemeasures,and
similar levels have been found in rapid (<1h)andconven-
tional autopsy tissue (up to 8 hours). Overall, these ﬁndings
support the idea that the unbalance between ROS generation
and detoxiﬁcation by antioxidants is an early event that plays
an important role in the progression of the disease.
3. ROS Generation and
Mitochondrial Dysfunction
In cells, multiple pathways and enzymes can generate ROS.
These include, as an example, complexes I and III of
the mitochondrial respiratory chain in the mitochondrion,
nicotinamide adenine dinucleotide phosphate (NADPH)
oxidase (NOX), xanthine oxidase, or nitric oxide synthase
(NOS)[8].MitochondriaproduceROSandreactivenitrogen
species (RNS) during the normal aerobic activity. This
accounts for the generation of superoxide (O
•
2
−), mainly
produced at complex I and complex III of the electron
transport chain, and nitric oxide (•NO). •NO controls
mitochondrial respiration and both cytotoxic, as well as
cytoprotective eﬀects have been described to be due to
this RNS. Depression of ATP synthesis through oxidative
phosphorylation by •NO has been mainly attributed to
the inhibition of mitochondrial complex IV. In fact, •NO-
induced inhibition of complex IV is completely and quickly
reverted upon its removal, suggesting that the inhibition of
mitochondrial complex IV by •NO can be better described
as a functional control of cell respiration [48]. Importantly,
if these two molecules (O
•
2
− and •NO) encounter each
other, they undergo a fast spontaneous reaction leading to
production of peroxynitrite (ONOO−). For this purpose,
classical antioxidant pathways, such as superoxide dismutase
(SOD2 in the matrix and also SOD1 at the intermembrane
space) and the glutathione cycle, play a relevant role in
detoxifying increased mitochondrial ROS levels. Although
it is unclear whether the decline in antioxidants precedes
the increase in oxidants during AD progression, their levels
are certainly not capable of neutralizing enhanced ROS
generation[44].Thus,mitochondriarequireeﬃcientexpres-
sion of antioxidant enzymes. In this perspective, oxidative
stress is also seen as an imbalance that has its origins in
genes and in the way in which gene expression is regulated.
At the center of this new focus is a transcription factor
named nuclear factor (erythroid-derived 2)-like 2, or Nrf2
(described further in this paper), the “master regulator” of
the antioxidant response, modulating the expression of hun-
dreds of genes, including the familiar antioxidant enzymes
[49].
Evidence from AD postmortem brain, as well as cellular
and animal AD models, shows that Aβ triggers mitochon-
drial dysfunction by interaction with diﬀerent mitochon-
drial targets, including the outer mitochondrial membrane
OMM, intermembrane space, inner mitochondrial mem-
brane IMM, and the matrix. The consequent impairment of
oxidative phosphorylation, ROS production, mitochondrial
dynamics, and the interaction with mitochondrial proteins
[50]m a yb er e l a t e dt oat o x i ce ﬀect caused by intracellular
Aβ. Indeed, Aβ has been described to accumulate intracellu-
larly, a process linked to early stages in the neuropathological
phenotype of AD [51]. Within the cells, aggregated Aβ1-
42 may appear as dense packed granules [52]. Moreover,
intracellular Aβ is present in mitochondria from brains
of AD transgenic mice and AD patients. Aβ progres-
sively accumulates in mitochondria and is associated with
decreased activity of complexes III and IV and a reduction
in the rate of oxygen consumption [53]. Importantly, Aβ
can be transported into mitochondria via the translocase
of the outer membrane (TOM) machinery in a process
independent of the mitochondrial membrane potential [54].
Concordantly, many studies have shown mitochondrial
abnormalities in AD, as expressed both by energy deﬁcits
and the potentially toxic production of free radicals [6].
Imaging and biochemical studies in brain and peripheral
samples obtained from AD patients revealed alterations
in both extramitochondrial and mitochondrial metabolic
pathways. Accordingly, reduced cerebral glucose transport
and pyruvate levels through glycolysis were observed in
the temporal cortex of AD subjects. Moreover, deregulation
of tricarboxylic acid cycle and oxidative phosphorylation
system coupled to altered mitochondrial dynamics were
also found [55, 56], along with the well-deﬁned deﬁcit in
mitochondrial complex IV [57]. Thus, mitochondria are
susceptibleorganellesinAD,largelycontributingfordisease-
related ROS generation and AD pathogenesis.
Both mitochondrial ROS production and Ca2+ handling
(which is necessary for the activity of mitochondrial dehy-
drogenases)areconsideredthecentreofimportantbiological
processes, and their deregulation has been implicated in a
number of human pathologies, including neurodegenerative
diseases like AD. Due to localized high Ca2+ concentration
in microdomains close to mitochondria, Ca2+ is rapidly
accumulated within mitochondria (e.g., [58]) inﬂuenc-
ing energy function by activating mitochondrial matrix
dehydrogenases to produce more NADH, donating more
electrons through complex I, and thus driving the synthesis
of ATP. Thus, the role of mitochondria as reservoirs of Ca2+
and apoptotic proteins and producers of ROS is patholog-
ically linked to neurotoxicity in both AD and aging brain.
However, most investigators agree that mitochondria from
AD subjects diﬀer from those of age-matched, nondemented
subjects [3, 59–61]. The role of mitochondrial ROS as
inducers of Ca2+ deregulation is well established, and a
major cause of ROS production has been linked to Ca2+
deregulation, along with reduced mitochondrial ATP levels.
Thus, oxidative stress and Ca2+ regulation are intricately
linked and can cooperatively contribute to AD pathogenesis
[60, 61].4 International Journal of Cell Biology
Apart from producing ROS and RNS, mitochondria are
susceptible targets for oxidant molecules. These can attack
mitochondrial lipids, proteins, and DNA. In fact, the lack
of histones in mtDNA renders them vulnerable organelles
to oxidative stress [7, 8]. Mitochondrial-targeted ROS scav-
engers, without interfering with physiological ROS signaling,
therefore represent a promising novel therapeutic approach
to the treatment of neurodegenerative diseases like AD [8,
60]. In recent studies the mitochondrial antioxidant MitoQ
(mitoquinone mesylate: [10-(4,5-dimethoxy-2-methyl-3,6-
dioxo-1,4-cycloheexadienl-yl) decyl triphenylphosphonium
methanesulfonate]) prevented increased production of ROS
andthelossofmitochondrialmembranepotentialincortical
neurons subjected to Aβ and further prevented cognitive
decline, synaptic loss, caspases activation, and oxidative
stress in female of 3xTg-AD mice [62].
To better access mitochondrial dynamics and how Aβ
aﬀects the function of this organelle, researchers mainly
use in vitro strategies. In pyramidal neurons from the
hippocampus of AD patients, the levels of intracellular Aβ1-
40 and −42 were found to be 3 and 10μM, respectively,
higher than those found in control individuals [63], which
are in the range of the concentrations used in numerous in
vitro studies. In fact, by using isolated rat brain mitochon-
dria treated with Aβ, both mitochondrial transmembrane
potential and the mitochondrial capacity to accumulate
Ca2+ were shown to be decreased and to cause a complete
uncoupling of respiration [64]. Moreover, mitochondrial
accumulation of Aβ reduced oxygen consumption and
mitochondrial electron transport chain activity [65, 66]. The
progressive accumulation of Aβ within this organelle was
shown to be linked to mitochondrial abnormalities, like
mtDNA defects and altered mitochondrial gene expression,
along with changes in mitochondrial dynamics [67], axonal
transport, and also synaptic degeneration [50, 60].
Deregulated Ca2+ levels are also detrimental to mito-
chondrial function, and therefore impaired Ca2+ homeosta-
sis may play a role in ROS generation, Aβ aggregation,
and damage to mitochondria in AD [68]. Aβ can further
promote intracellular Ca2+ increase in a deleterious positive
feedback loop [69], suggesting that Aβ accumulation can
deregulate Ca2+ levels and vice versa. In fact, L-, P- and N-
type Ca2+ channels activity can be modulated by Aβ,a n
eﬀect apparently mediated primarily by Aβ-induced ROS
production [68]. Aβ was also shown to promote excessive
release of Ca2+ from endoplasmic reticulum (ER), which
may underlie mitochondrial Ca2+ dyshomeostasis and ROS
generation, thereby disturbing organelle functioning and,
ultimately, damaging neurons [55], as described above.
Themildorgradualenergydisturbance,describedabove,
may inﬂuence ROS generation (namely, through disruption
of the mitochondrial respiratory chain) and cause the
oxidative damage of diﬀerent molecules and the formation
of the high conductance mitochondrial cyclophilin D-
associated permeability transition pore (PTP) [70]. This is
followed by the release of proapoptotic factors, particularly
cytochrome c and apoptosis-inducing factor (AIF) and the
activation of caspases in charge of the “execution” phase
of the apoptotic cascade [71]. In this perspective, apoptosis
through the intrinsic pathway has been largely described
to play an essential role in AD pathogenesis [72]. In
response to apoptotic signals, loss of mitochondrial mem-
brane potential associates with mitochondrial membrane
permeabilization to evoke cytochrome c release and the
activation of the initiator caspase-9. Nevertheless, evidence
of apoptosis has been largely controversial in AD. Although
many reports support the occurrence of mitochondrial-
linked apoptosis, as observed following exposure to Aβ,
other researchers have not seen an increase in apoptosis.
Previous reports described that the hippocampus of AD
brains displayed DNA fragmentation, but only few cells
showed morphological characteristics of apoptosis [73]. This
has been opposed by studies in cell and animal models of
AD overexpressing the antiapoptotic protein Bcl-2. In this
regard, we previously showed that Bcl-2 is neuroprotective
against apoptotic cell death caused by Aβ(25–35) [74].
Additionally, overexpression of Bcl-2 in 3xTg-AD mice
improved place recognition memory, reduced caspase acti-
vation, and attenuated APP processing, leading to decreased
formationofextracellularplaquesandneuroﬁbrillarytangles
[75].
3.1. Oxidative Stress and Synaptic Loss: The Relevance of
Synaptic Mitochondria. Synapses are sites of high energy
demand and extensive Ca2+ ﬂuctuations since synaptic
transmission requires high levels of ATP and constant
regulation of intracellular Ca2+ concentration, rendering
synaptic mitochondria vital for maintenance of synaptic
function and transmission [59].
Recent studies in postmortem frontal cortex obtained
from MCI individuals or mild/moderate and late-stage
AD patients demonstrated a signiﬁcant disease-dependent
increase in oxidative markers mainly localized to the
synapses. Interestingly, the levels of oxidative markers sig-
niﬁcantly correlate with MMSE suggesting an involvement
of oxidative stress in AD-related synaptic loss [44]. A
recent study also demonstrated mitochondrial morphologic
alterations in neurons obtained from diﬀerent brain areas
of postmortem human AD brains concomitantly, with loss
of dendritic branches and depletion of dendritic spines
[76]. In AD, synaptic dysfunction and the loss of synapses
are in fact early pathological features, probably due to
defects in synaptic mitochondria, which lead to alterations
in cognitive function [44], and, interestingly, this seems to
be related to ROS production and altered Ca2+ dynamics at
the synapse [61]. In mouse hippocampal neurons, Aβ was
demonstrated to impair mitochondrial movements, reduce
mitochondrial length, and cause synaptic degeneration
[77]. Compared with nonsynaptic mitochondria, synaptic
mitochondria showed a greater degree of age-dependent
accumulation of Aβ and mitochondrial alterations. The
fact that synaptic mitochondria, especially Aβ-rich synaptic
mitochondria, are more susceptible to Aβ-induced damage
highlights the central importance of synaptic mitochon-
drial dysfunction to the development of synaptic degen-
eration in AD [59]. Indeed, synaptic mitochondria are
more sensitive to ROS than nonsynaptic mitochondria
[78].International Journal of Cell Biology 5
In AD, synapses are the primary sites of Ca2+ deregu-
lation due to overactivation of glutamate receptors. These
receptors are concentrated on postsynaptic spines of neu-
ronal dendrites where they are subjected to particularly high
levels of Ca2+ inﬂux, oxidative stress, and ATP demand.
Therefore, they are likely sites at which neurodegenerative
processes are initiated in aging and early AD, thus playing an
important role in decreased synaptic function. In addition,
the apoptotic process has been shown to be activated locally
in synaptic compartments after exposure to Aβ in vulnerable
AD neuronal populations [79].
With this in mind, in the next section we discuss the role
of N-methyl-D-aspartate receptors (NMDARs), a subtype of
glutamate receptors, in mitochondrial Ca2+ regulation and
ROS formation in AD-associated neurodegeneration.
3.2. Role of NMDA Receptors in AD. Ionotropic glutamate
receptors mediate most excitatory neuronal transmission
in the brain and play essential roles in the regulation of
synaptic activity. In fact, Ca2+ inﬂux through NMDARs
induced by synaptic activity is required for many types of
synaptic plasticity and underlies some forms of learning and
memory. Very recently, the selective roles for GluN2A and
GluN2B subunits of the NMDARs in long-term potentia-
tion (LTP) and long-term depression (LTD), respectively,
were reported [80]. However, excessive Ca2+ inﬂux due to
overactivation of NMDARs may result in excitotoxic cell
death in many neurological disorders, including AD [81]
(Figure 1).
Depending on their speciﬁc response to diﬀerent phar-
macological agents, ionotropic glutamate receptors can be
subdivided into NMDARs, α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA) and kainate receptors [81,
82]. Aβ oligomers were shown to induce inward currents,
intracellular Ca2+ increase, mitochondrial Ca2+ overload,
oxidative stress, mitochondrial membrane depolarization,
and apoptotic cell death through a mechanism requiring
NMDAR and AMPAR activation in both rat cortical neurons
and hippocampal organotypic slices [69].
Functional NMDARs are heterotetramers composed of
two glycine-binding GluN1 subunits assembling with two
glutamate-binding GluN2 (GluN2A–GluN2D) subunits or,
alternatively, GluN3 (GluN3A and/or GluN3B) subunits
which can replace GluN2 [83]. The most widely expressed
NMDARs contain the obligatory subunit GluN1 plus either
GluN2B or GluN2A or a mixture of the two. GluN2B and
GluN2D subunits are expressed at high levels in early devel-
opmental stages (prenatally), whereas GluN2A and GluN2C
expression is ﬁrst detected near birth [84]. NMDARs exhibit
highCa2+ permeabilityandvoltage-dependentchannelblock
by extracellular Mg2+ [81], properties of both physiological
and pathological importance. Channel blockade by Mg2+
reduces Ca2+ inﬂux at membrane voltages near rest but is
relieved during neuronal excitation [81].
Recent studies have reported activation of the ROS-
producing NOX after NMDAR stimulation in response to
intrastriataladministrationofglutamateinmice.Incontrast,
mice lacking NOX2 were less vulnerable to excitotoxicity,
presented reduced levels of ROS production and protein
nitrosylation, decreased microglial reactivity and calpain
activation, suggesting that NOX is stimulated by Ca2+ entry
through ionotropic glutamate receptors [85]. Recent results
also demonstrate that not only glutamate excitotoxicity
and/oroxidativestressaltermitochondrialﬁssion/fusion,but
that an imbalance in mitochondrial ﬁssion/fusion in turn
leads to NMDAR upregulation and oxidative stress [86],
suggestinganewviciouscycleinvolvedinneurodegeneration
that includes glutamate excitotoxicity, oxidative stress, and
mitochondrial dynamics.
Although NMDARs activation is essential for memory
formation, therapeutic actions of memantine, an uncompet-
itive open channel blocker of NMDARs, include slowing of
neuronal loss due to NMDARs excitotoxicity, thus correcting
for an excitation-inhibition imbalance. Indeed, memantine
is widely prescribed as a memory-preserving drug for
moderate- to late-stage AD patients [87], suggesting that
the therapeutic eﬀect of memantine derives predominantly
from NMDARs inhibition. However, it appears paradoxical
that inhibition of NMDARs slows memory loss associated
withAD,consideringthatNMDARsactivationisessentialfor
memory formation.
Aβ oligomers were previously reported to coimmuno-
precipitate with extracellular domains of the GluN1 subunit,
suggesting a direct interaction of Aβ with NMDARs [88].
UsingtransfectedHEK293cells,ithaspreviouslybeenshown
that Aβ mediates necrotic cell death through changes in
Ca2+ homeostasis in HEK293 cells selectively expressing
GluN1/GluN2A subunits, but not GluN1/GluN2B subunits
[84]. However, in rat primary cortical cultures it was
recently demonstrated that Aβ1-42 preparation containing
both oligomers (in higher percentage) and monomers
directly interacts with cell function by disturbing intra-
cellular Ca2+ homeostasis through activation of GluN2B-
containing NMDARs [89]. Moreover, the same preparation
ofAβ1-42inducedmicrotubuledisassembly,reducedneurite
length and DNA fragmentation in mature hippocampal
cells, which were largely prevented by the selective NMDAR
antagonists MK-801 (noncompetitive antagonist), meman-
tine and ifenprodil (GluN2B subunit antagonist), suggesting
a role for extrasynaptic GluN2B-containing NMDARs in
Aβ toxicity, as recently shown by Mota and colleagues
(in press).
Application of Aβ monomers and low-n oligomers
(dimers and trimers) secreted from Chinese hamster ovary
cells that stably overexpress human APP bearing the
Val717Phe familial AD mutation was shown to mimic a state
of partial NMDAR blockade, reducing NMDAR activity and
NMDAR-dependent Ca2+ inﬂux [90]. Accordingly, neurons
from a genetic mouse model of AD were found to express
reduced amounts of surface GluN1 subunit [91], and Aβ1-
42 was also found to reduce surface expression of the GluN1
subunit, in both cortical and hippocampal neurons [91,
92]. On the other hand, GluN2A- and GluN2B-NMDARs
appear to have opposite roles in regulating intracellular
Ca2+ in the presence of Aβ1-42 in rat cortical cultures
[89]. These ﬁndings support the concept that dysregulation6 International Journal of Cell Biology
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Figure 1:SourcesofreactiveoxygenspeciesinAlzheimer’sdisease.ExtracellularaccumulationofAβ maydirectorindirectlyalterNMDARs-
mediated glutamatergic neurotransmission with concomitant cytosolic Ca2+ increase and impaired synaptic activity. Excitotoxic increase in
glutamatergic neurotransmissionmay activate extrasynaptic NMDARs leading to a massive increase inthe intracelular Ca2+,which is rapidly
taken up by mitochondria and ER. Mitochondria Ca2+ overload promotes the generation of ROS. Additionally, the ER may also promote
ROS production. Decreased PDI activity may lead to polyubiquitinated proteins accumulation, which may thus induce the UPR, mediated
by IRE1α, PERK, and ATF6 pathways. In order to cope with the need to balance disulﬁde bond formation, the activity of ERO1α is increased
leading to the production of ROS that are able to directly attack and aﬀect IP3R function. Since the ER and the mitochondria are in close
proximity, the Ca2+ released from the ER, through the IP3R, can then enter directly into mitochondria, through the VDAC or the MCU,
leading to the increase in mitochondrial Ca2+ content, inducing mitochondrial ROS production. As a result of prolonged ER stress, CHOP
may induce ERO1α upregulation or activate the enzyme CaMKII, which can further activate NOX, localized at the plasma membrane,
enhancing cytosolic ROS production. As a consequence, protective antioxidant defenses such as GSH are depleted. In addition, Nrf2, which
normally translocates to the nucleus where it activates the antioxidant response element, may be retained in the cytosol.International Journal of Cell Biology 7
of intracellular Ca2+ homeostasis is induced by a possible
interaction of Aβ with NMDARs, particularly of the GluN2B
subtype. In addition, it was also demonstrated that in the
AD brain and human cortical neurons, excitatory synapses
containing the GluN2B subunit of the NMDAR appear to be
the main sites of oligomer accumulation. In this study, Aβ
oligomers colocalized with synaptic markers, and this eﬀect
was counteracted by ifenprodil and memantine, blocking the
ion channel formed by the NMDAR [93].
There is a growing body of evidence that NMDAR activ-
ity has the potential to promote survival or death in neurons
of the central nervous system [94], which may be related
to diﬀerences in synaptic versus extrasynaptic NMDAR
signaling. It was recently demonstrated that extrasynaptic,
but not synaptic, NMDARs activity stimulates neuronal
amyloidogenic β-secretase-mediated APP processing and
increases Aβ production in primary cultures of cortical neu-
rons [95]. Interestingly, in this study, memantine inhibited
extrasynaptic NMDAR-induced APP protein expression as
well as neuronal Aβ release in a dose-dependent manner. In
fact,thediﬀerencesbetweensynapticandextrasynapticpools
could be due to the way they are activated: brief saturating
activation in the case of synaptic NMDARs, compared with
chronic, low-level activation of extrasynaptic NMDARs by
bath application of glutamate. Diﬀerences in the properties
of intracellular Ca2+ transients evoked by these diﬀerent
stimuli may diﬀerentially aﬀect signaling, even if the overall
Ca2+ load is similar [96, 97].
Ca2+ inﬂux through NMDARs activation also seems to
have opposite consequences on neuronal fate, according to
their cellular localization [98, 99]. Stimulation of synaptic
NMDARs induces prosurvival events through the activa-
tion of cAMP response element-binding protein (CREB)
[100] and the extracellular signal-regulated kinase (ERK)
cascade [101]. Conversely, Ca2+ inﬂux through extrasynaptic
NMDARs overrides these functions coupling to a dominant
CREB shut-oﬀ pathway causing CREB dephosphorylation,
which is less well tolerated, triggering decreased mitochon-
drial membrane potential and cell death [99]. Thus, a
distinct NMDARs activation signaling pathway was postu-
lated,dependingontheirlocalization.Synapticstimulievoke
Ca2+entry through both GluN2A- and GluN2B-containing
NMDARs and, in contrast to excitotoxic activation of
extrasynaptic NMDARs, produce only low-amplitude cyto-
plasmic Ca2+ spikes and modest nondamaging mitochon-
drial Ca2+ accumulation [102]. However, NMDAR signaling
can also be due to diﬀerences in the composition of the
NMDARs as opposed to the location of the receptors. Thus,
it has been suggested that excitotoxicity is triggered by the
selective activation of NMDARs containing the GluN2B
subunit [103, 104] irrespective of its location (synaptic or
extrasynaptic), as GluN2A-containing NMDARs promote
survival [104]. Accordingly, Ca2+ entering through GluN2A
or GluN2B subunits-containing NMDARs was shown to
haveantiapoptoticactivityormitochondrialdysfunctionand
cell death, respectively [100].
4. ERand OxidativeStressinAD
4.1. ER Stress and ER-Mitochondria Crosstalk in AD
4.1.1. ER Stress in AD. The ER is a multifunctional organelle
that plays a central role in many essential cellular activities,
suchasfolding,assemblyandqualitycontrolofsecretoryand
membraneproteins,disulﬁdebondformation,glycosylation,
lipid biosynthesis, Ca2+ storage and signaling. Under stress
conditions, such as perturbed Ca2+ homeostasis or redox
status, elevated secretory protein synthesis rates, altered gly-
cosylationlevels,andhypercholesterolemia,unfoldedormis-
folded proteins accumulate in the ER lumen leading to ER
stress [105]. To relieve stress and reestablish homeostasis, the
ER activates intracellular signal transduction pathways, col-
lectively termed the unfolded protein response (UPR),which
reduces the inﬂux of newly synthesized proteins into the ER
throughinductionofgeneraltranslationalarrestandinduces
thetranscriptionalupregulationofgenesthatenhancetheER
protein-folding capacity and quality control. During UPR,
the ER also employs proteasomal (ER-associated degrada-
tion, ERAD) and autophagic pathways to degrade mis- or
unfolded proteins [106]. Three specialized ER stress-sensing
proteins involved in the canonical mammalian UPR pathway
have been identiﬁed: protein kinase R-like endoplasmic
reticulum kinase (PERK), inositol-requiring enzyme 1 α
(IRE1α) and activating transcription factor 6 (ATF6). Upon
ER stress, the ER chaperone glucose-regulated protein 78
(Grp78) dissociates from these ER transmembrane sensors
and promotes their activation, inducing phosphorylation
and oligomerization of IRE1, and PERK, and translocation
of ATF6 to the Golgi where it is cleaved by Site 1 and Site 2
proteases (S1P and S2P). Active IRE1α processes the mRNA
encoding X-box binding protein 1 (XBP1), a transcription
factor that upregulates genes encoding mediators of protein
folding, ERAD, organelle biogenesis, and protein quality
control. PERK activation reduces protein load in the ER by
decreasing general protein synthesis through phosphoryla-
tion of the initiation factor eukaryotic initiation factor 2
(eIF2α) which paradoxically increases selective translation of
activating transcription factor 4 (ATF4) mRNA. The ATF4
protein is a member of the bZIP family of transcription
factors that activates the expression of several UPR target
genes involved in antioxidant responses, apoptosis, and
autophagy. In ER stressed cells, ATF6 is cleaved at the Golgi
apparatus, and the released cytosolic domain translocates to
the nucleus where it increases the expression of ER chaper-
ones,ERAD-relatedgenes,andproteinsinvolvedinorganelle
biogenesis. However, when ER stress is prolonged or too
severe, these adaptive mechanisms fail to restore protein-
folding homeostasis, thus shifting adaptive programs toward
the induction of apoptotic signaling to eliminate irreversibly
damaged cells [107].
Unresolved and prolonged ER stress leads to perturbed
Ca2+ homeostasis, increased protein accumulation, loss of
ER function, and activation of apoptotic cascades [106].
Under these conditions, the level of the UPR-induced
cell death mediator C/EBP-homologous protein (CHOP)
increases [108] and activates the transcription of GADD34,8 International Journal of Cell Biology
which interacts with protein phosphatase I to catalyze eIF2α
dephosphorylation [109, 110]. Dephosphorylated eIF2α in
turn increases protein synthesis and oxidation leading to ER
p r o t e i no v e r l o a d[ 111]. CHOP also represses the transcrip-
tion of the antiapoptotic Bcl-2 protein [112]. Accordingly,
deletion of CHOP gene partially protects both cells and
animals from ER stress-mediated cell death [113]. The UPR
is known to initiate other proapoptotic events as well,
including c-Jun N-terminal kinase (JNK) phosphorylation,
cleavage of ER-speciﬁc caspases such as caspase-12, and
disruption of cellular Ca2+ homeostasis [114].
Inthepastfewyears,ERstresshasbeenlargelyimplicated
in the pathogenesis of multiple human diseases, includ-
ing neurodegenerative disorders [107, 115]. Several studies
support that UPR activation upon ER stress is one of the
main players in synaptic dysfunction and neuronal death
occurring in AD [116–118]. In postmortem brain tissues
from AD patients, a signiﬁcant increase in the levels of ER
stress markers, including phospho-PERK, phospho-eIF2α,
and phospho-IRE1α, the transcription factor XBP1, the
chaperone Grp78, and the downstream mediator of cell
deathCHOPhasbeenreported,comparedwithage-matched
controls, suggesting that the prolonged activation of the ER
stress response is involved in the neurodegenerative process
in AD [119–122]. Furthermore, recent studies revealed a
connection between UPR activation and autophagic pathol-
ogy in AD brain since the levels of microtuble-associated
protein light chain 3 (LC3), an autophagosome marker,
are increased in neurons displaying UPR activation [123].
Recent evidence obtained in an AD transgenic mice model,
in which caspase-12, Grp78 and CHOP are strongly up-
regulated, further implicates ER stress induction in the
pathogenesis of AD [124]. Familial AD-linked presenilin-
1 (PS-1) mutations downregulate the UPR and lead to ER
stress vulnerability [125]. The mechanisms by which mutant
PS-1 aﬀects the ER stress response are attributed to the
inhibited activation of ER stress transducers such as IRE1α,
PERK, and ATF6. On the other hand, in sporadic AD, it was
found that the aberrant splicing isoform (PS2V), generated
by exon 5 skipping of the presenilin-2 (PS-2) gene transcript,
downregulates the signaling pathway of the UPR [126].
Familial and sporadic AD are both associated with
increased Aβ levels in brain parenchyma. Several evidences
support that Aβ deposition and ER stress are interrelated
events in AD. A global molecular proﬁle of hippocampal
and cortical gene expression revealed that ER stress-related
genes are diﬀerentially regulated during the initial and
intermediate stages of Aβ deposition [127]. ER stress was
shown to enhance γ-secretase activity, as well as Aβ secretion
[128]. On the other hand, it was proposed that Aβ is
generated within the ER lumen as a result of deﬁcits in
axonal transport [129]. It was also found that in transgenic
mice expressing APP(E693Δ) (APP(OSK)) intraneuronal Aβ
oligomersaccumulateintheERinhippocampalneuronsand
cause cell death by inducing ER stress [130]. Additionally,
the involvement of caspase-12 activation in Aβ-induced
synaptic toxicity was recently demonstrated in cortical and
hippocampal synaptosomes isolated from 3xTg-AD mice
[131]. Several evidences demonstrate that Aβ is also able to
trigger an ER stress response in vitro [132–134]. In primary
cortical neurons, both ﬁbrillar and oligomeric Aβ have been
shown to upregulate Grp78 concomitantly with activation of
the ER stress-mediated apoptotic cell death pathway [135,
136]. How Aβ causes ER stress is presently unclear. However,
recent evidences obtained in cultured hippocampal neurons
support that interaction of Aβ oligomers with NMDAR, in
particular with the GluN2B subunits, occurs upstream of
d e r eg u l a t i o no fE RC a 2+ homeostasis and upregulation of ER
stress markers (Costa et al., unpublished data).
Perturbation of ER Ca2+ homeostasis, a trigger for the
accumulation of unfolded or misfolded proteins and activa-
tion of the ER stress response, seems to play an important
role in the onset or progression of neuronal dysfunction
in AD [117, 137]. Signiﬁcantly, a markedly decrease of
calreticulinimmunoreactivity(ERCa2+ bindingprotein)was
described in AD postmortem brain [138]. Recent studies
in AD transgenic mice have shown that enhanced Ca2+
response is associated with increased levels of ryanodine
receptors and altering synaptic transmission and plasticity
mechanismsbeforetheonsetofhistopathologyandcognitive
deﬁcits [139, 140]. Moreover, mutant PS-1 interacts with the
inositol-1,4,5-trisphosphate (IP3)r e c e p t o r( I P 3R)-associated
Ca2+ release channel, resulting in Ca2+ signalling abnor-
malities [141, 142] that have been suggested to be an early
pathogenic event in AD involved in presynaptic dysfunction
[143]. Recently, it was discovered that PS-1 and PS-2 can
form low-conductance channels, leading to passive ER Ca2+
leak [144]. These results provided potential explanation for
abnormal Ca2+ signaling observed in familial AD cells with
mutations in PSs. Several ﬁndings also implicate Aβ as a
trigger of ER Ca2+ dyshomeostasis. APP overexpression was
shown to potentiate CHOP induction and cell death in
response to ER Ca2+ depletion [145]. Similarly, Aβ depletes
ER Ca2+ through IP3R- and RyR-mediated Ca2+ release, thus
increasing intracellular Ca2+ levels and compromising cell
survival [136, 146]. In addition, Aβ-induced perturbation
of intracellular Ca2+ homeostasis in neurons was shown to
be correlated with an increase of the speciﬁc isoform of the
ryanodine Ca2+ channel RyR3 expression and activity [147].
Recent evidences suggest that strategies able to amelio-
rate ER stress can prevent Aβ pathology. 4-Phenylbutyrate
(PBA), acting through its chemical chaperone-like activity
and via the transcriptional activation of a cluster of proteins
required for the induction of synaptic plasticity and struc-
tural remodeling, was shown to mitigate ER stress. In the
Tg2576 mouse model of AD, ER stress was accompanied by
reversal of learning deﬁcits, clearance of intraneuronal Aβ
accumulation, and restoration of dendritic spine densities
of hippocampal CA1 pyramidal neurons [148]. Additionally,
the same authors demonstrated that chronic administration
of PBA, starting before the onset of disease symptoms, pre-
vents age-related memory deﬁcits in Tg2576 mice, associated
to a decrease in Aβ pathologyandinﬂammation[148].Wiley
andcolleagues[149]alsodemonstratedthatPBAameliorates
the cognitive and pathological features of AD in the APP-
swePS1delta9 AD transgenic mice. In APP-overexpressing
cells, PBA blocked the repressive eﬀects of the ER stressors
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activation, and apoptosis [150]. Furthermore, silencing
CHOP gene expression was shown to protect against AD-
like pathology triggered by 27-hydroxycholesterol in rabbit
hippocampus [151]. Recently, it was demonstrated that
activation of the PERK-eIF2α UPR pathway prevents Aβ-
induced neuronal ER stress [152]. Furthermore, the active
form of the transcription factor XBP1 was shown to be neu-
roprotective in ﬂies expressing Aβ and mammalian cultured
neurons treated with Aβ oligomers, which was mediated by
the downregulation of RyR3, preventing the accumulation
of free Ca2+ in the cytosol [153]. In addition, dantrolene
and xestospongin C, pharmacological inhibitors of ER Ca2+
release, were shown to prevent Aβ-induced apoptotic cell
death [154, 155].
4.1.2. ER-Mitochondria Crosstalk in AD. ER stress-induced
apoptotic cell death involves a mitochondrial component
[156, 157]. ER directly communicates with mitochondria
through close contacts referred as mitochondria-associated
membranes (MAMs) that promote Ca2+ transfer from ER to
mitochondria thus maintaining mitochondrial metabolism
and cell survival [158–160]. The molecular bridges that
regulate the contacts between ER and mitochondria include
the IP3R on the ER and the VDAC, which are physically
coupled through the cytosolic chaperone glucose-regulated
protein 75kDa (Grp75) [161]. In addition, the dynamin-
related GTPase mitofusin 2 (Mfn2) on the ER forms
homoheterodimers with Mfn1 or Mfn2 on mitochondria to
keepthetightcontactsbetweenthetwoorganelles.Moreover,
PACS-2 (mainly localized at the ER) and dynamin-related
GTPase protein 1(Drp1) indirectly control the distance
between the two organelles through regulation of mitochon-
drial morphology and distribution [162]. The chaperone
S i g m a - 1r e c e p t o r( S i g - 1 R )i sa b l et os e n s eC a 2+ concentra-
tions in the ER and controls the amount of Ca2+ released
through the IP3R that can be transmitted to mitochondria
[163].
Disruption of contact sites and impairment of Ca2+
coupling between ER and mitochondria have profound
consequences for cellular function and in extreme cases
lead to apoptosis. In fact, decreasing the space between
both organelles promotes mitochondrial Ca2+ overload
that can lead to the opening of the PTP, dissipation of
the mitochondrial membrane potential and activation of
apoptotic cell death [164], and, on the other hand, an
increase in the distance between the two compartments
inhibits Ca2+ transmission, compromising Ca2+-dependent
regulation of mitochondrial metabolism and consequently
cell viability [165]. Accordingly, during the adaptive phase
of ER stress, an early increase in cellular bioenergetics and
mitochondrial metabolism occurs [166] but during the cell
death response, ER stress exerts profound deleterious eﬀects
on mitochondrial function [167] and activates an apoptotic
pathway which depends crucially upon Ca2+ transfer from
the ER to the mitochondria [135, 168]. The MAM is
responsible for this transfer since its disruption, achieved
by siRNA knockdown of PACS-2, results in the inhibition
of ER Ca2+release and apoptosis onset [162]. Furthermore,
apoptoticstimuliknowntoactthroughCa2+ releasefromthe
ER induce a prolonged increase in the mitochondrial Ca2+
concentration [154, 155, 169, 170].
Several members of the Bcl-2 family, such as Bcl-2 itself,
Bax and Bak, naturally localize to both mitochondria and
the ER and modulate Ca2+ content in both organelles,
controlling the amount of ER-releasable Ca2+ that can reach
mitochondria triggering apoptotic cell death [154, 171–176].
Transmission of a Ca2+ signal from ER to mitochondria was
demonstrated to be associated with IP3-induced opening
of PTP and, in turn, cytochrome c release [177]. Similarly,
phosphorylation of IP3R by Akt reduces cellular sensitivity
to apoptotic stimuli through a mechanism that involves
diminishedCa2+ ﬂuxfromtheERtothemitochondria[178].
Cytochrome c released from mitochondria can also bind to
ER IP3Ra n dp r o m o t e sC a 2+ release through this channel
[179]. Released ER Ca2+ triggers the extrusion of a large
amount of cytochrome c from all the mitochondria in the
cell, amplifying the death signal [180, 181]. It has been
reported that mobilization of Drp1 to mitochondria, under
ER Ca2+ release conditions, can trigger mitochondrial cristae
remodelling, facilitating cytochrome c release and subse-
quent apoptosis [182, 183]. However, recruitment of Drp1 to
mitochondria upon sustained Ca2+ release from the ER was
describedtoprotectfromapoptosisbyfragmentingthemito-
chondrial network and blocking Ca2+ transmission [184].
Despite the evidence that demonstrates the involvement
of mitochondrial and ER dysfunction in AD pathogen-
esis [55], the role of ER-mitochondria crosstalk in this
neurodegenerative disorder has not been clariﬁed so far.
It was recently shown that PS-1 and PS-2 are highly
enriched in a subcompartment of the ER that is related
with MAM [185]. In SH-SY5Y cells and primary neuronal
cultures, overexpression of PS-2, and more drastically its
familial AD mutants, was demonstrated to increase the
physical interaction between ER and mitochondria thus
facilitating mitochondrial Ca2+ uptake [186]. Moreover,
the association of hyperphosphorylated tau with ER mem-
branes was detected in AD brains and also in the brain
of asymptomatic mice that overexpress mutant tau [187].
Interestingly,thesemiceexhibitedmorecontactsbetweenER
membranesandmitochondria,suggestingthataccumulation
of tau at the surface of ER membranes might contribute
to tau-induced neurodegeneration through impairment of
mitochondrial function [187]. Recent studies performed in
mtDNA-depleted ρ0 cells challenged with toxic Aβ described
the activation of an ER stress-induced apoptotic cell death
pathway that requires the presence of a functional mitochon-
drial [188]. In Aβ-treated cortical neurons, it was previously
demonstrated that Ca2+ released from ER, through IP3R
and RyR channels [146], is implicated in the depolarization
of the mitochondrial membrane, release of cytochrome c
upon translocation of Bax to mitochondria and activation of
caspase-9 [135, 136], thus implicating the ER/mitochondria
crosstalkinneurodegenerationoccurringuponAβ exposure.
This communication was also corroborated by the evidence
obtained with cybrids, which recapitulate the mitochondrial
defect (inhibition of complex IV of the electron transport
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of ER stress-induced apoptotic cell death were shown to
be increased by Aβ treatment in comparison with controls
suggesting that Aβ-induced ER stress is enhanced under
mitochondrial dysfunction conditions [190].
4.2. ER-Driven ROS Production. Numerous evidences clearly
implicate oxidative stress in AD pathogenesis. In this respect,
the ﬁrst thing that comes to our mind is mitochondrial-
driven ROS generation. However, could ER be another
important source of ROS in AD? Mainly during protein
synthesis, 25% of cellular ROS are produced in the ER as a
consequence of the activity of oxidoreductases, a family of
proteins that catalyze protein folding reactions [191–193].
After the entry of nascent proteins in the ER, disulﬁde bond
formation must occur to ensure their correct maturation
and function. This reaction is catalyzed by the protein
disulﬁde isomerase (PDI) that accepts electrons from thiol
residues in the polypeptide chain substrate leading to its
oxidation [194, 195]. To continue its activity, PDI must be
reoxidized, a process that is guaranteed by oxidoreductin
1( E R O 1 )[ 196]. In order to recycle itself, ERO1 transfers
electrons to molecular oxygen, leading to the production
of ROS. In AD patients, no substantial alterations were
o b s e r v e di nP D Il e v e l sw h e nc o m p a r e dt oc o n t r o l s[ 197];
however this may not imply about its net activity. In fact,
it was reported that the activity of PDI may be inhibited
by •NO, since increased levels of S-nitrosylated PDI were
found in the brain of sporadic AD patients [198]. As a
consequence, polyubiquitinated proteins accumulate, which
may thus activate the UPR [198].
The ROS formation due to ERO1 activity is not exclu-
sively linked to protein folding. ERO1 is retained in the ER
through its interaction with PDI and the ERp44 [199, 200].
Beside this interaction, ERp44 also binds to the IP3R leading
to its inhibition, a process that is dependent on pH, Ca2+
concentration and redox state [201]. In this way, ERp44
works as a sensor of the environment in the ER lumen. When
this ERp44-IP3R connection is disrupted, ER Ca2+ is released
through this channel into the cytosol. This process may rely
on the presence of ERO1, since prolonged ERO1 activation
is expected to originate a hyperoxidizing environment in the
ERlumen[202],whichmayleadtotheformationofdisulﬁde
bondsintheIP3R[201],disruptingtherepressiveinteraction
b e t w e e nE R p 4 4a n dI P 3R[ 203]. Interestingly, ERO1α,o n eo f
the two ERO1 proteins expressed in human, was described
to be localized on MAM [204], which is highly enriched in
IP3R[ 205], suggesting that human ERO1α regulates IP3R-
Ca2+ signaling on the MAM [204]. The Ca2+ released from
ER can then enter directly into mitochondria, through the
O M MV D A Co rt h eI M MC a 2+ uniporter (MCU), leading
to the increase in mitochondrial Ca2+ content [206], ROS
production, and the opening of the PTP [207, 208]. This
sequence of events is expected to occur in AD and can
be hypothesized to underlie the increase in cellular ROS
triggered upon ER Ca2+ release observed in Aβ-treated
cortical neurons [135]( Figure 1).
Several ER functions, such as chaperone-mediated pro-
tein folding and refolding and the maintenance of Ca2+
gradients, are ATP-dependent processes. During the UPR,
ER chaperones like Grp78 are upregulated, and consequently
higher levels of ATP must be delivered to the ER, requir-
ing an increase in ATP production by the mitochondrial
respiratory chain, with the consequent enhancement of
ROS production [209]. Similarly, the ER Ca2+ leak that
occurs under prolonged stress conditions could obligate
the sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA) to
increase the rate of entry of Ca2+ to the ER lumen, causing
ATP depletion and subsequent increase of ROS production
within the mitochondria.
Another consequence of UPR activation, in an attempt
to recover from protein unfolding or misfolding, is the
depletion of the antioxidant GSH. The function of GSH
in the ER needs to be fully elucidated; however it has
been suggested that GSH acts as a reductant [210], either
by maintaining ER oxidoreductases in a reduced state
or by directly reducing nonnative disulphide bonds in
substrate folding proteins [211]. This may explain why
the ER lumen contains a relatively high concentration of
oxidized glutathione (GSSG), driving the GSH: GSSG ratio
to approximately 3:1 [192, 212]. During UPR, the overload
of unfolded proteins enhances ERO1 activity, leading to
an increase in oxidized PDI levels, which requires higher
levels of GSH. The subsequent conversion to GSSG leads to
a depletion of the GSH pool. Another hypothesis for this
decrease is that the stimulation of ERO1 activity increases
the generation of ROS that reacts with GSH, decreasing its
levels, which further increases ROS levels (Figure 1). In AD,
contradictory results concerning GSH levels have emerged.
Adams and colleagues [213] have suggested that GSH levels
increase in the AD brain as a compensatory mechanism
following damage in speciﬁc brain regions. In an opposite
manner, Aksenov and coworkers [214] have reported that
GSH metabolism is compromised in aﬀected brain regions
of AD patients. Moreover, GSH levels were described to be
decreased in red blood cells from male AD patients and in
experimentalmodelsofAD[215,216].Ithasbeenpreviously
shown that GSH levels decrease in cortical neurons treated
with Aβ, and this decrease was correlated with the release of
Ca2+ from the ER [168]. This datum is further supported
by previous results showing that depletion of GSH occurs
in neurons treated with Aβ ﬁbrils [217]. Therefore, Aβ-
driven GSH depletion might contribute to the impairment
of quality control mechanisms operating at the ER, leading
to the accumulation of unfolded/misfolded proteins.
GSH is not the only antioxidant defense that may be
reduced in AD as a consequence of ER stress and ROS
formation. When the UPR is induced, the ER senses the
increase in ROS and increases antioxidant defenses, namely,
through the PERK signaling pathway that coordinates the
convergence of ER and oxidative stress. One of these
antioxidant responses involves the phosphorylation of Nrf2
by PERK, followed by its dissociation from the microtubule-
associated protein Keap1 (Kelch-like Ech-associated protein
1), which allows the dislocation of Nrf2 from the cytosol
to the nucleus [209, 218]. Once in the nucleus, Nrf2 binds
to the antioxidant response element (ARE) to activate the
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antioxidant enzymes [219]. Nrf2 activation also contributes
to the maintenance of GSH levels, which in turn buﬀers the
accumulation of ROS during the UPR [220]. Several studies
allow us to speculate that the increase in ROS observed in
AD may be linked, at least in part, to a deregulation of
Nrf2 activity (Figure 1). Indeed, not only Nrf2 was described
to be predominantly cytoplasmatic in hippocampal neurons
from AD patients, resulting in decreased nuclear levels [221],
but also Nrf2-ARE pathway was shown to be attenuated
in APP/PS1 transgenic mouse brain at the time of Aβ
deposition [222]. The potential protective role of Nrf2 in AD
is further supported by the demonstration of a signiﬁcant
reduction in spatial learning deﬁcits of aged APP/PS1 mice,
observedwhenNrf2isoverexpressedinthisADmodel[222].
When ER stress is prolonged, UPR signaling pathways
ultimately lead to apoptosis. CHOP is one of the mediators
of ER stress-mediated apoptotic cell death. Li and colleagues
[223] have demonstrated that CHOP induces ERO1α upreg-
ulation,whichcausestheactivationoftheERIP3R.TheCa2+
released from ER can enter the mitochondria, promoting
ROS generation as described above, but can also activate
the enzyme calcium/calmodulin-dependent protein kinase II
(CaMKII),whichtriggersmitochondrial-mediatedapoptosis
[224]( Figure 1). CaMKII can further induce NOX that acti-
vates a protein kinase R (PKR-) activating protein, leading
to sustained PKR-mediated CHOP expression, amplifying
the pathway induced by this ER stress-related transcription
factor [225]. In AD patients, during the initial stages of the
disease,theexpressionofall3isoformsofNOXwasshownto
be signiﬁcantly increased [226], activating NOX-associated
pathways and contributing to AD progression [45]. The
connection between CHOP upregulation and NOX signaling
in AD remains to be further clariﬁed but it seems to be
a good target for future therapeutic perspectives. Another
positive feedback is played by ROS itself that can sensitize
both Ca2+-release channels and SERCA at the ER membrane
[227–229].ROS or RNS can oxidize critical thiols in the RyR,
causing Ca2+ release [230]. On the other hand, oxidation
of SERCA inhibits their ability to transport Ca2+ to the ER
lumen, increasing cytosolic Ca2+ concentration [228].
From the data exposed above it is possible to conclude
that the ER could be, by its nature, an important source
of ROS in AD, which impacts on cell survival upon
perturbation of normal ER function. Due to the close
communication between ER and mitochondria, ER stress
occurring in AD brain can be expanded to the mitochondria
releasing its malicious oxidative power that can further
trigger apoptotic cell death pathways. Therefore, targeting
these cellular sources of ROS may bring strong therapeutical
outcomes for this neurodegenerative disease.
5.OxidativeStressMarkersin
Biological Fluidsfrom ADPatients
With the move towards development of disease-modifying
treatments, there is a need for more accurate diagnosis of
AD in its early stages. Therefore, much attention has been
paidtotheidentiﬁcationandvalidationofbiologicalmarkers
of the disease. Markers that speciﬁcally reﬂect the onset
of pathology may have a profound impact both on early
diagnosis and on detection of treatment eﬀects in the near
future. Established CSF biomarkers exist for early AD: total
and hyperphosphorylated tau (tau and p-tau) that reﬂect
AD-type axonal degeneration and the 42 amino acid isoform
of amyloid β (Aβ1-42) that reﬂects senile plaque pathology
[231]. These biomarkers have recently been incorporated
in the new proposed revised criteria for AD [232, 233].
However, these classical markers do not capture all the
pathological changes that take place in the brain of AD
patients, and its clinical application is limited by the invasive
nature of its collection. Impaired bioenergetics, increased
production of ROS, and oxidative injury are, as seen above,
important features of AD pathology that occur early in
the course of the disease. These ﬁndings have spurred the
developmentofassaysformarkersthatreﬂecttheseprocesses
both in tissue, CSF and peripheral ﬂuids.
Themethodologymostlyusedtoassessoxidativedamage
is through the detection of products of free radical attack
against biomolecules (lipids, proteins, and nucleic acids).
Additionally, several compounds of the antioxidant defense
system can be measured and used as complementary infor-
mation regarding the oxidant/antioxidant balance of the
organism.
Results on lipid peroxidation in plasma and peripheral
blood cells have been inconsistent, with several authors
demonstrating increased levels of free MDA or TBARS in
serum/plasma [234–239] or in erythrocytes [240, 241]o fA D
patients and MCI subjects, whereas others did not conﬁrm
these ﬁndings [242–244]. Interestingly, a few studies have
shown that the highest TBARS levels were found in APOE-
ε4 carriers [13, 241], suggesting that APOE genotype aﬀects
the extent of the oxidative stress-induced damage.
Free HNE has also been assessed in ventricular CSF from
patientswithAD,andsigniﬁcantlyelevatedlevelswerefound
in comparison to age-matched controls, while no diﬀerences
were detected in the levels of HNE-protein adducts [245].
Similar to what has been reported for MDA and TBARS,
the results of the determination of HNE in peripheral ﬂuids
of AD and MCI subjects have been somewhat inconclusive.
Some authors have demonstrated elevated plasma levels of
HNE in AD patients, compared to controls [243, 246], while
others did not observe any diﬀerences [247]. An interesting
study [248] reported increased levels of MDA and HNE in
peripheral cells (skin ﬁbroblasts and lymphoblasts) derived
fromfamilialADpatients,carryingAPPandPS-1mutations,
while no diﬀerences in these lipid peroxidation markers were
found between sporadic AD cases and controls.
Increased levels of F2-IsoPs were also found both in
postmortem ventricular CSF from AD patients [20, 249]a n d
in lumbar CSF collected in vivo [250, 251], correlating with
clinical severity and other biomarkers of the disease, like CSF
Aβ1-42 and tau [252, 253]. Several studies on MCI subjects
also found increased levels of CSF F2-IsoPs [251, 254, 255],
including longitudinal studies, that have shown that CSF F2-
IsoPs levels rise after 12-month followup [254] and that the
rate of increase is higher in MCI subjects that progress to
AD, compared to healthy controls and stable MCI [256]. In12 International Journal of Cell Biology
fact, longitudinal evaluation of CSF F2-IsoPs seems to be
useful in predicting future cognitive deterioration both in
cognitive normal and MCI subjects and in increasing the
diagnostic accuracy of prodromal AD [255, 257]. One study
in particular [258] suggests that the determination of CSF
isoprostanes could be useful in monitoring the eﬀectiveness
of experimental antioxidant treatments. The quantiﬁcation
of isoprostanes in peripheral ﬂuids of AD patients and MCI
subjectshashoweveryieldedconﬂictingresults.Somestudies
have found elevated levels of F2-IsoPs in the urine [252, 259]
andplasmaofADpatients[252]andMCIsubjects[251],but
further studies did not conﬁrm these results [260, 261].
Overall, it seems that data regarding oxidative damage
to lipids in the central nervous system is fairly consistent
in showing increased markers of lipid peroxidation in early
stages of AD. However, when moving to peripheral ﬂuids,
results are rather conﬂicting. Methodological diﬀerences
could in part explain these contrary results. Furthermore,
multiplephysiologicalandpathologicalconditionscaninﬂu-
ence the levels of lipid oxidative damage in peripheral ﬂuids,
such as diet, physical activity, smoking habits, and comor-
bidities like diabetes, cardiovascular disease, and cancer
that are known to increase oxidative damage. Therefore,
when analysing the levels of lipid peroxidation markers in
peripheral ﬂuids in AD patients and MCI subjects, it is
extremely important to control for potential confounders.
Protein carbonyls are usually detected with 2, 4-
dinitrophenylhydrazine (DNPH) by a simple spectropho-
tometric assay. Carbonyl content has also been studied in
plasma, with some studies failing to show an increase in this
protein oxidation marker in AD patients [243, 262]a n dM C I
subjects [241]. Recent studies, however, have demonstrated
increased plasma concentrations of protein carbonyls in AD
patients and MCI subjects, compared to controls [263], and
also in peripheral lymphocytes isolated from AD patients
[246].
Protein nitration, detected by nitrotyrosine immunore-
activity, has been studied not only in the brain but also in
CSF.ByemployingsensitiveHPLCmethods,ﬁve-toeightfold
increases in the levels of 3-NT have been found in the
ventricular and lumbar CSF of AD patients when compared
with cognitively normal controls [264, 265]. These results,
however, were not conﬁrmed by a diﬀerent study using a gas
chromatography coupled with mass spectroscopy approach
[266], where the majority of AD patients had 3-NT CSF
levelssimilartothecontrols.Thediscrepanciesbetweenthese
studies are probably due to the diﬀerent sample preparation
and analysis methods and to the possible in vitro formation
of 3-NT in the CSF samples. Similarly to what has been
shown for protein carbonyls, increased levels of 3-NT have
alsobeenreportedinplasmaandlymphocytesofADpatients
compared to controls [124].
DNA injury, assessed through increased levels of 8-
OhdG, has also been shown in intact DNA extracted
from ventricular CSF [267, 268]o ri nl u m b a rC S Fo fA D
patients [269]. Studies using DNA extracted from peripheral
tissue have also demonstrated increased levels of DNA
oxidation, thus suggesting the systemic nature of oxidative
damage in AD. Increased levels of 8-OHdG and oxidized
purines and pyrimidines in the peripheral lymphocytes and
leukocytes of AD and MCI patients have been demonstrated
[235, 270, 271] and also an increased urinary excretion of
oxidized nucleosides in AD patients [272]. The potential
of DNA oxidation levels as a biomarker for AD has been
questioned, however, due to the overlap between AD and
controls and to its lack of speciﬁcity, as increased DNA
oxidation seems to be present in other neurodegenera-
tive conditions, such as amyotrophic lateral sclerosis and
Parkinson’s disease [272]. Besides DNA, oxidation of RNA
can also be used as a marker of oxidative stress, through
the determination of 8-OHG levels. Interestingly, those
were found to be ﬁvefold increased in the CSF of AD
patients compared to controls, being unaltered in the serum
[273].
Contradictory results have been reported regarding the
peripheral activity of cellular antioxidant enzymes in AD
patients. While some studies have not found any diﬀerences
in the activity of these enzymes in red blood cells of AD
o rM C Is u b j e c t sa sc o m p a r e dt oc o n t r o l s[ 234, 241, 242],
others have reported an increased activity of glutathione
peroxidase, catalase, and superoxide dismutase [236, 239,
240], but decreased activity of the latter enzymes has
also been found [238, 274, 275]. Regarding nonenzymatic
antioxidants, including glutathione, uric acid, carotene,
lycophene, vitamins A, C, and E, work from several groups
has demonstrated decreased plasmatic levels in AD patients
[234, 269, 276]a n dM C Is u b j e c t s[ 263, 275, 276], with some
authors suggesting that progression to AD might be related
to depletion of antioxidant defenses [277]. One of the most
investigated nonenzymatic antioxidants is probably vitamin
E, the most powerful chain-breaking antioxidant [278], with
reduced levels reported not only in plasma [234, 241, 275,
276] but also in CSF [279] and brain parenchyma of AD
patients [280]. Antioxidant intervention in animal models
of AD showed a signiﬁcant reduction in oxidative stress, Aβ
deposition, and also behavioral improvements [281, 282].
However, in AD clinical trials, antioxidants have shown only
a marginal positive eﬀect on disease progression [283, 284],
and subsequent MCI trials with antioxidants indicate that
vitamin E ingestion has no beneﬁt on the risk of progression
to AD [285, 286]. The lack of success of these trials [287–
289] likely arises from a combination of factors, including
using the wrong dose in an unbalanced monotherapy, not
monitoring the drug levels and surrogate markers for the in
vivo therapeutic eﬀect of the drug of interest and starting
the therapy very late in the disease stage. The failure of
simple antioxidants to reverse ROS damage has prompted
the need of other mitochondrial-targeted therapies, such
as acetyl-L-carnitine-carnitine (a compound that acts as
an intracellular carrier of acetyl groups across the inner
mitochondrial membrane), MitoVitE (a compound that
results from the conjugation of vitamin E with the lipophilic
triphenylphosphonium cation—TPP+—making the antiox-
idant selectively accumulateinside the mitochondria), Szeto-
Schiller peptides (small cell permeable antioxidants that
target mitochondria in a potential-independent manner),
or Dimebon (the Russian antihistamine laterpirdine), as
reviewed elsewhere [290, 291].International Journal of Cell Biology 13
The failure of antioxidant therapy to attenuate disease
progression [285, 286] might also be explained by the fact
that oxidative stress could be a necessary but insuﬃcient
factorforthedevelopmentofdisease,thatisdependentupon
additional factor(s) for the onset of underlying pathogenesis.
Nevertheless, early intervention to prevent chronic oxidative
stress, and thereby ameliorate one of the factors for the
development of the disease, should inﬂuence and reduce
the risk of ever developing the disease. Indeed, the role of
oxidative stress in the pathogenesis of AD has moved from
an epiphenomenon to one of the earliest events in disease
pathogenesis, occurring prior to the onset of symptoms and
associated with the brain regions typically aﬀected in the
disease [14, 28, 38–40, 43, 251]. The hypothesis, based on in
vitro cell culture experiments, that Aβ causes oxidative stress
[1] has been challenged by in vivo studies where oxidative
stress chronologically precedes Aβ deposition. In fact, Aβ
accumulation is associated with reduced levels of oxidative
stress [38–40]. Therefore, the identiﬁcation of valuable
reliable peripheral markers of oxidative damage would be of
utmost importance for researchers and clinicians. Currently
there isn’t no single biomarker of oxidative stress. The stan-
dardization of assessment methods and the consideration
of potential confounders are critical to reduce the inconsis-
tencies that have been reported between studies. Moreover,
many of these studies have been done by comparing AD
patients and/or MCI subjects with healthy controls and not
withotherneurodegenerativediseases,sospeciﬁcityisstillan
issue.Oxidativestresshasbeenfoundincreasinglyimplicated
in a number of neurodegenerative disorders including AD,
Parkinson’s disease (PD), and amyotrophic lateral sclerosis
(ALS) [292]. However, even if a process is not speciﬁc to AD
pathogenesis, such as oxidative damage, its biomarkers may
be useful in the context of clinical and imaging studies to
monitor disease progression and optimize therapy. Increased
sensitivity and speciﬁcity can probably be achieved by using
ap a n e lo fd i ﬀerent biochemical indices that target diﬀerent
pathological processes and can provide a more accurate
picture of the oxidative balance of the organism.
6. Concluding Remarks
Alzheimer’s disease (AD) is the most common age-related
dementia. It is a slowly progressive and chronic neurode-
generative disorder, in which cognitive impairment is related
to synapses degeneration and neuronal death occurring
in the limbic system and speciﬁc regions of the cerebral
cortex. The accumulation of Aβ in senile plaques and
the intraneuronal aggregates of hyperphosphorylated tau
protein are recognized hallmarks of the disease whose cause
still remains unknown.
Several lines of evidence show that mitochondria dys-
function, Ca2+ deregulation, and oxidative stress are promi-
nent factors in AD cellular pathology. Mitochondria, where
free oxygen radicals are generated as by-products from
the electron transport chain and from enzymes of the
tricarboxylic acid cycle, are main sources and simultaneously
main targets of ROS.
Toxic Aβ oligomersmayinduceCa2+ inﬂuxintoneurons,
rendering neurons vulnerable to excitotoxicity, through the
activation of glutamate NMDAR, and apoptosis. Glutamate
excitotoxicity and/or oxidative stress have been shown to
alter mitochondrial ﬁssion/fusion and an imbalance in
mitochondria dynamics in turn leads to NMDAR upreg-
ulation and oxidative stress. In addition, Aβ accumulates
in mitochondria and thereby impairs the activity of mito-
chondria respiratory chain and reduces ATP synthesis and
the mitochondria Ca2+ buﬀering capacity, causing elevated
cytoplasmic Ca2+ levels and oxidative stress.
Aβ was also shown to promote ER stress and excessive
release of Ca2+ from ER which may underlie mitochon-
drial Ca2+ dyshomeostasis and ROS generation, thereby
disturbing organelle functioning and, ultimately, damaging
neurons.
Mitochondria and the ER are closely linked morpho-
logically and functionally, and considerable crosstalk of cell
death proteins, promoted by ROS and high Ca2+ levels,
occurs between these two organelles. The Ca2+ transport
systems of the ER are also sensitive to oxidative stress being
directly exposed to ER/mitochondria-generated ROS. The
resulting abnormal cellular Ca2+ load can trigger cell death
by activating proteases, reinforcing signals leading to caspase
activation, such as cytochrome c release from mitochondria,
or by triggering other catabolic processes mediated by lipases
and nucleases.
Aβ-associatedCa2+ deregulation,impairedbioenergetics,
increased production of ROS, and oxidative injury to lipids,
proteins, and nucleic acids, associated to impairment of
antioxidant defences, are important features of AD cellular
pathology that occur early in the course of the disease.
It can be hypothesized that the progression to AD may
be related to the incapacity of the antioxidant system to
counterbalance the oxidative injury, leading to disruption
of cell redox signaling. In this context, development of
reliable oxidative stress biomarkers and new antioxidant
strategies should be proposed as primary prevention mea-
sures, even before signiﬁcant plaque deposition or cognitive
decline.
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